Premedication after grade 1 infusion reaction

Vantrexa · Metastatic NSCLC

MI-2026-0615RoutineClosedWithin SLAEscalatedSafety

RARachel AdeyemiMSL, Oncology (UK & Ireland)

Restricted — potential adverse event

Access limited to Medical Information and Safety roles. Details are captured minimally and routed to pharmacovigilance per SOP-PV-014. AI features are disabled for this record (PRD §27.7).

Received: 26 Apr 2026, 16:12 UTC
Channel: Web portal
Requestor type: Patient
Country / region / team: United Kingdom · Europe · MI Europe
Category: Safety
Response type: Custom response
Owner: RARachel Adeyemi
Due: 01 May 2026, 16:12 UTC
Responded: 27 Apr 2026, 17:12 UTC
Quality review: Passed
Related insight: —
Related standard response: None matched (topic-keyword match)

Workflow

12-stage inquiry workflow (PRD §16). Advancing records an audit event.

Received
Triage
Assigned
In progress
Escalated
Draft response
Medical review
Quality review
Sent
Follow-up required
11Closed
12Archived

Current stageClosedDemo action — not persisted

SLA

Routine: 120 h target · Routine 120 h / Urgent 48 h / Critical 24 h

SLA hours

120

Elapsed

25 h

to response

Remaining

95 h

21%

Timeline

01 May 2026, 16:12 UTC
SLA due (120 h)
26 Apr 2026, 16:12 UTC
Received via Web portal
Patient · United Kingdom
26 Apr 2026, 16:12 UTC
Triage and assignment
Urgency Routine · assigned to MI Europe
26 Apr 2026, 16:12 UTC
Escalated
Safety flag — routed to pharmacovigilance
27 Apr 2026, 17:12 UTC
Response sent
Custom response · quality review passed

Draft response

Restricted record

AI suggestion disabled — safety-flagged inquiries are not interpreted by AI (PRD §27.7).

Draft response

Audit history

No audit events for this record

Create, update, approve and export events appear here with user, timestamp, previous and new values.

Data lineage: MI inquiry platform (IRMS, INT-05) · received 26 Apr 2026 · hourly sync.